Promotion of Research and Innovation in Pharma MedTech Sector Scheme

Why in news

  • Government approved Rs 1,600 crore in financial assistance for 41 pharma and MedTech innovation projects under the first call of PRIP.

Key terms

PRIP Scheme

Promotion of Research and Innovation in Pharma-MedTech Sector scheme aimed at promoting breakthrough drug discovery.

Biosimilars

Biological medical products highly similar to already approved reference biopharmaceuticals with no clinical differences.

Complex Generics

Generic drugs with complex active ingredients, formulations, or routes of delivery requiring advanced R&D.

CAR-T Therapy

Chimeric Antigen Receptor T-cell therapy, an immunotherapy altering T-cells genetically to target cancer cells.

What is the PRIP Scheme?

  • Launched by Department of Pharmaceuticals to shift Indian pharma from high-volume generic production to high-value innovation.
  • Provides financial grants to establish Centres of Excellence and support R&D in priority focus areas across industry and academia.
  • Encourages private sector R&D expenditure through public co-funding mechanisms.

Key focus areas and approved grants

  • Approved 41 projects expected to catalyze Rs 3,020 crore of private investment, bringing total R&D pipeline value to Rs 4,620 crore.
  • Covers 27 projects in New Chemical Entities/Medicines, 5 in Complex Generics and Biosimilars, and 9 in Novel Medical Devices.
  • Supports 19 MSME/startup projects alongside 22 large domestic pharmaceutical firm ventures.

Why it matters

  • Addresses critical vulnerabilities in biologicals, CAR-T cell therapies, advanced diagnostics, and antimicrobial resistance (AMR) novel drugs.
  • Strengthens domestic IP creation and export value addition beyond standard low-margin generic formulation manufacturing.

Prelims facts

  • PRIP target priority areas include New Chemical Entities, Biosimilars, and High-End Medical Devices.

Mains discussion

  • Transition of Indian pharmaceutical industry from the world's pharmacy of generics to an innovation-led intellectual property hub.

Source: PIB Press Release

Same topic · past papers

UPSC has asked this before

These previous-year questions sit on the same topic. Open one to practise the earlier ask.

  1. 2024 · Q145 · UPPGS

    With reference to the “National Intellectual Property Rights Policy” consider the following statements: 1. It reiterates India's commitment to Doha Development Agenda and the TRIPS agreement. 2. Department of Industrial Policy and Promotion is the nodal agency for regulating Intellectual Property Rights in India. Which of the above statements is/are correct? Select the correct answer from the code given below:

    View answer →

← All Prelims + Mains notes for 1 October 2026

PDF
Daily news · PIB · quiz — Free